PFIZER INC.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Assessment Of Efficacy and Safety UK-390,957 In Men With Premature Ejaculation
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2012-11-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 138
- Registration Number
- NCT00219635
- Locations
- ๐ฌ๐ง
Pfizer Investigational Site, Devon, United Kingdom
Assessment Of Efficacy and Safety Of UK-390,957 In Men With Premature Ejaculation
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2012-11-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 460
- Registration Number
- NCT00219583
- Locations
- ๐น๐ท
Pfizer Investigational Site, Balcova, Izmir, Turkey
Assessment Of Safety Of UK-390,957
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2012-11-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1058
- Registration Number
- NCT00219609
- Locations
- ๐ฌ๐ง
Pfizer Investigational Site, Devon, United Kingdom
Dalacin-T Gel Post Approval Study
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-05-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 134
- Registration Number
- NCT00219570
A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2008-05-05
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00220363
- Locations
- ๐ฉ๐ช
Schwarz, Monheim, Germany
Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2008-11-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00220376
- Locations
- ๐บ๐ธ
Schwarz, RTP, North Carolina, United States
Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2008-11-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00220402
- Locations
- ๐ฉ๐ช
Schwarz, Monheim, Germany
Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00220389
- Locations
- ๐บ๐ธ
Schwarz, RTP, North Carolina, United States
AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2019-05-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 111
- Registration Number
- NCT00219557
- Locations
- ๐บ๐ธ
Southeast Nebraska Cancer Center, Southeast Nebraska Hematology and Oncology Consultants, P.C., Lincoln, Nebraska, United States
๐จ๐ฆCross Cancer Institute, Edmonton, Alberta, Canada
๐บ๐ธEast Bay Medical Oncology/Hematology Medical Associates, Inc., Concord, California, United States
Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2013-04-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 7609
- Registration Number
- NCT00205777
- Locations
- ๐ช๐ธ
Pfizer Investigational Site, Madrid, Spain
ยฉ Copyright 2024. All Rights Reserved by MedPath